 |
|
Drug-Induced, Ro/SSA-Positive Cutaneous Lupus Erythematosus
Monika Srivastava, BS;
Adrienne Rencic, MD, PhD;
Gerardine Diglio, BS;
Helen Santana, BS;
Paula Bonitz, BS;
Rosemarie Watson, MD;
Esther Ha, BA;
Grant J. Anhalt, MD;
Thomas T. Provost, MD;
Carlos H. Nousari, MD
Arch Dermatol. 2003;139:45-49.
Objective To study the clinical and immunopathologic findings of drug-induced, Ro/SSA-positive cutaneous lupus erythematosus (CLE).
Design Retrospective medical and laboratory record review.
Setting Immunodermatology Division of Johns Hopkins Hospital (Baltimore, Md).
Patients Of 120 patients found to have anti-Ro/SSA antibodies by hemagglutination and/or double immunodiffusion, 70 had clinical and immunopathologic confirmation of CLE. Fifteen of these 70 patients had a history of new drug exposure, defined as less than 6 months, associated with disease development.
Results The disease-associated drugs included hydrochlorothiazide (5 patients), angiotensin-converting enzyme inhibitors (3 patients), calcium channel blockers (3 patients), interferons (2 patients), and statins (2 patients). The most common presentations were photodistributed diffuse erythema and subacute CLE-type lesions without evidence of significant systemic disease. All specimens revealed interface dermatitis and fine granular IgG deposition along the basement membrane zone and throughout the epidermis. Most patients experienced improvement or resolution of clinical lesions within 8 weeks and decrease of Ro/SSA titers within 8 months after discontinuation of drug treatment.
Conclusions Antihypertensive drugs are the most commonly associated with Ro-positive CLE. Clinical and immunopathologic features of this drug-induced variant do not seem to differ from the idiopathic disease. In most cases, the disease improves or resolves on discontinuation of the offending drug treatment. It is not known if these drugs precipitate disease in patients who have subclinical disease. Drug-induced Ro/SSA-positive CLE should be included on the differential diagnosis in patients presenting with photosensitive or subacute CLE-type eruptions.
From the Division of Immunodermatology, Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Md. Dr Nousari is now with the Division of Dermatopathology, Department of Dermatology, University of Pennsylvania, Philadelphia.
RELATED ARTICLE
How Frequently Are Drugs Associated With the Development or Exacerbation of Subacute Cutaneous Lupus?
Jeffrey P. Callen
Arch Dermatol. 2003;139(1):89-90.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus
Han et al.
Int Immunol 2008;20:1067-1075.
ABSTRACT
| FULL TEXT
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial
Ferreira et al.
Rheumatology (Oxford) 2007;46:1560-1565.
ABSTRACT
| FULL TEXT
Drug-induced lupus: an update
Vasoo
Lupus 2006;15:757-761.
ABSTRACT
UV-B Phototoxic Effects Induced by Atorvastatin.
Marguery et al.
Arch Dermatol 2006;142:1082-1084.
FULL TEXT
Inhalation Route Inducing Subacute Cutaneous Lupus Erythematosus With Tiotropium
Pham and Saurat
Arch Dermatol 2005;141:911-912.
FULL TEXT
Statins: immunomodulators for autoimmune rheumatic disease?
Jury and Ehrenstein
Lupus 2005;14:192-196.
ABSTRACT
Ro/SSA-Positive Cutaneous Lupus Erythematosus Induced by Carbamazepine
Capponi et al.
Arch Dermatol 2005;141:103-104.
FULL TEXT
Statins and lupus erythematosus
Noel
Rheumatology (Oxford) 2004;43:397-398.
FULL TEXT
Risks and Benefits of Statins in Lupus Erythematosus
Noel
Arch Intern Med 2004;164:107-108.
FULL TEXT
Frequency of Drug-Induced Cutaneous Lupus Erythematosus
Journal Watch Dermatology 2003;2003:5-5.
FULL TEXT
How Frequently Are Drugs Associated With the Development or Exacerbation of Subacute Cutaneous Lupus?
Callen
Arch Dermatol 2003;139:89-90.
FULL TEXT
|
